RBC Capital Maintains Outperform on IGM Biosciences, Raises Price Target to $20
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams maintains an Outperform rating on IGM Biosciences and raises the price target from $17 to $20.
October 18, 2024 | 12:27 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital has increased the price target for IGM Biosciences from $17 to $20, maintaining an Outperform rating. This suggests confidence in the company's future performance.
The increase in price target from $17 to $20 by RBC Capital, along with the maintained Outperform rating, indicates a positive outlook on IGM Biosciences' future performance. This is likely to boost investor confidence and potentially lead to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100